This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, congenital haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII deficiency, and Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions or where platelets are not readily available.1

NovoSeven® is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.1,2

1.

NovoSeven® Summary of Product Characteristics. SFDA Label.

2.

Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.

3.

Hoffman M Dargaud Y. J Thromb Haemost 2012;10:1478–1485.

4.

Demartis F et al. TH Open 2017;1:e130–e138.

5.

Maahs J et al. J Blood Med 2014;5:153–156.

6.

FEIBA® Summary of Product Characteristics.

7.

Neufeld EJ et al. Haemophilia 2011;17:650–656.

8.

Neufeld EJ et al. Blood Rev 2015;29(S1):S34–S41.

9.

Neufeld EJ et al. Haemophilia 2018;24(4):e275–e277.

10.

Hedner U. Blood Rev 2015;29(S1):S4–S8.

11.

Santagostino E et al., Thromb Haemost 2006;4(2):367–371.

12.

Neufeld EJ et al. Pediatr Blood Cancer 2013;60(7):1178–1183.

13.

Pruthi RK et al. Thromb Haemost 2007;98(4):726–732.

14.

Shapiro AD et al. Thromb Haemost 1998;80(5):773–778.

15.

Parameswaran R et al. Haemophilia 2005;11(2):100–106.

16.

National Hemophilia Foundation. MASAC Update. December 06, 2018.

17.

Susen S et al. Haemophilia 2019;25:731–737.

18.

Salek SZ et al. Haemophilia 2011;17(1):95-102.

19.

ClinicalTrials.gov. Changes to NCT02795767 on 04/06/2017. https://clinicaltrials.gov/archive/ NCT02795767/2017_06_04/changes [Accessed February 2018].

20.

ClinicalTrials.gov. NCT03020160. https://clinicaltrials.gov/ct2/show/record/ NCT03020160 [Accessed February 2018].

21.

Oldenburg J et al. N Engl J Med 2017;377(Supplement):809–818.

22.

Hemlibra® Summary of Product Characteristics.

23.

Levy GG, et al. J Thromb Haemost 2019 May 24. doi: 10.1111/jth.14491. [Epub ahead of print]

24.

Obergfell A et al. Haemophilia 2008;14(2):233–241.

25.

Hvid I and Rodriguez-Merchan EC. Haemophilia, 2002;8(3):288–291.

26.

Rexen P et al. TH Open 2019;3:e45–e49.

27.

Pollard D et al. J Haem Pract 2017;4(1):1–5.

28.

Hay CR et al. Thromb Haemost 1997;7(8):1463–1467.

29.

Amano K et al. Haemophilia 2016;23(1):50–58.

30.

Baudo F et al. Blood 2012;120(1):39–46.

31.

Borel-Derlon A et al. Haemophilia 2016;22 Suppl 4:3–138. Poster PO-W-4.

32.

Sumner MJ et al. Haemophilia 2007;13(5):451–461.

33.

Lentz SR et al. J Blood Med 2014;5:1–3.

34.

Sun B et al. Br J Haematol 2019. doi: 10.1111/bjh.16128. [Epub ahead of print].

35.

Pardos-Gea J et al. Haemophilia 2018;24(3):e163–e166.

36.

Tiede A, Worster A. Ann Hematol 2018;97(10):1889–1901.

37.

Abshire T, Kenet G. Haemophilia 2008;14(5):898–902.

38.

National Hemophilia Foundation. MASAC Update. December 06, 2018.